Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FXR1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FXR1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FXR1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FXR1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FXR1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FXR1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200102031 | Oral cavity | NEOLP | regulation of response to DNA damage stimulus | 43/2005 | 219/18723 | 6.13e-05 | 8.19e-04 | 43 |
GO:003424922 | Oral cavity | NEOLP | negative regulation of cellular amide metabolic process | 50/2005 | 273/18723 | 1.05e-04 | 1.27e-03 | 50 |
GO:004427031 | Oral cavity | NEOLP | cellular nitrogen compound catabolic process | 74/2005 | 451/18723 | 1.24e-04 | 1.47e-03 | 74 |
GO:200063731 | Oral cavity | NEOLP | positive regulation of gene silencing by miRNA | 11/2005 | 30/18723 | 1.63e-04 | 1.81e-03 | 11 |
GO:001714822 | Oral cavity | NEOLP | negative regulation of translation | 45/2005 | 245/18723 | 2.13e-04 | 2.26e-03 | 45 |
GO:001943931 | Oral cavity | NEOLP | aromatic compound catabolic process | 75/2005 | 467/18723 | 2.22e-04 | 2.34e-03 | 75 |
GO:006014831 | Oral cavity | NEOLP | positive regulation of posttranscriptional gene silencing | 11/2005 | 31/18723 | 2.28e-04 | 2.38e-03 | 11 |
GO:006014732 | Oral cavity | NEOLP | regulation of posttranscriptional gene silencing | 15/2005 | 52/18723 | 2.53e-04 | 2.59e-03 | 15 |
GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
GO:006096822 | Oral cavity | NEOLP | regulation of gene silencing | 20/2005 | 81/18723 | 2.69e-04 | 2.71e-03 | 20 |
GO:006096632 | Oral cavity | NEOLP | regulation of gene silencing by RNA | 15/2005 | 53/18723 | 3.19e-04 | 3.11e-03 | 15 |
GO:006096432 | Oral cavity | NEOLP | regulation of gene silencing by miRNA | 14/2005 | 49/18723 | 4.50e-04 | 4.04e-03 | 14 |
GO:190136131 | Oral cavity | NEOLP | organic cyclic compound catabolic process | 77/2005 | 495/18723 | 4.96e-04 | 4.40e-03 | 77 |
GO:006053813 | Oral cavity | NEOLP | skeletal muscle organ development | 32/2005 | 166/18723 | 7.05e-04 | 5.81e-03 | 32 |
GO:012003231 | Oral cavity | NEOLP | regulation of plasma membrane bounded cell projection assembly | 33/2005 | 186/18723 | 2.50e-03 | 1.58e-02 | 33 |
GO:006049131 | Oral cavity | NEOLP | regulation of cell projection assembly | 33/2005 | 188/18723 | 2.98e-03 | 1.82e-02 | 33 |
GO:200102221 | Oral cavity | NEOLP | positive regulation of response to DNA damage stimulus | 21/2005 | 105/18723 | 3.45e-03 | 2.05e-02 | 21 |
GO:000641718 | Prostate | BPH | regulation of translation | 157/3107 | 468/18723 | 9.09e-20 | 5.63e-17 | 157 |
GO:190331116 | Prostate | BPH | regulation of mRNA metabolic process | 111/3107 | 288/18723 | 2.28e-19 | 1.17e-16 | 111 |
GO:000838018 | Prostate | BPH | RNA splicing | 147/3107 | 434/18723 | 5.17e-19 | 2.29e-16 | 147 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FXR1 | SNV | Missense_Mutation | | c.1837N>C | p.Glu613Gln | p.E613Q | P51114 | protein_coding | tolerated_low_confidence(0.55) | benign(0.043) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
FXR1 | SNV | Missense_Mutation | | c.1628N>A | p.Arg543Lys | p.R543K | P51114 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.899) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FXR1 | SNV | Missense_Mutation | | c.916N>C | p.Glu306Gln | p.E306Q | P51114 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FXR1 | SNV | Missense_Mutation | rs755691527 | c.786N>A | p.Phe262Leu | p.F262L | P51114 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FXR1 | SNV | Missense_Mutation | | c.1094N>C | p.Arg365Thr | p.R365T | P51114 | protein_coding | tolerated(0.06) | benign(0.432) | TCGA-E9-A1N4-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
FXR1 | SNV | Missense_Mutation | novel | c.754G>A | p.Ala252Thr | p.A252T | P51114 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FXR1 | SNV | Missense_Mutation | rs371485992 | c.1298G>A | p.Arg433Gln | p.R433Q | P51114 | protein_coding | tolerated(0.22) | probably_damaging(0.968) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FXR1 | SNV | Missense_Mutation | rs751470533 | c.1765G>A | p.Asp589Asn | p.D589N | P51114 | protein_coding | deleterious_low_confidence(0.04) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FXR1 | SNV | Missense_Mutation | | c.298N>C | p.Asp100His | p.D100H | P51114 | protein_coding | deleterious(0) | possibly_damaging(0.813) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
FXR1 | SNV | Missense_Mutation | | c.411N>C | p.Leu137Phe | p.L137F | P51114 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |